$1.59
-0.02 (-1.24%)
Open$1.64
Previous Close$1.61
Day High$1.64
Day Low$1.56
52W High$39.92
52W Low$1.50
Volume—
Avg Volume89.1K
Market Cap7.39M
P/E Ratio—
EPS$-7.93
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+900.0% upside
Current
$1.59
$1.59
Target
$15.90
$15.90
$11.92
$15.90 avg
$19.90
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.64M | 3.84M | 3.77M |
| Net Income | 720.4K | 800.4K | 930.4K |
| Profit Margin | 19.8% | 20.8% | 24.7% |
| EBITDA | 1.38M | 1.54M | 1.32M |
| Free Cash Flow | 559.4K | 545.0K | 561.2K |
| Rev Growth | +15.7% | +20.7% | +9.8% |
| Debt/Equity | 0.34 | 0.35 | 0.37 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $263.29 | -1.12% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $423.64 | +1.32% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $151.28 | -0.61% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $526.73 | -0.18% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $750.51 | -0.23% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $254.07 | -0.51% | 41.4 | 33.44B |